Vanda's Motion Sickness Drug Faces More Delays
Vanda Pharmaceuticals' (VNDA) tradipitant approval delayed again as FDA extends clinical hold review while labeling issues emerge for the motion sickness treatment.
/ 1665 items
#XY↓
HeartBeam Pursues Multiple Paths After FDA Setback
HeartBeam responds to FDA's NSE decision on its 12-lead ECG software with appeal plans and labeling modifications to advance heart monitoring technology.
Clear Street Maintains Buy on Nuvation Bio Despite Pipeline Adjustment
Clear Street keeps $12 price target on NUVB after NUV-1511 discontinuation, citing blockbuster potential for IBTROZI and safusidenib programs.
Piper Sandler Upgrades Oscar Health to Overweight, Sees Strong Profit Potential
Piper Sandler upgrades Oscar Health to Overweight with a $25 price target, citing growth and profitability potential through 2027.
FDA Grants Priority Review to BeOne’s New Drug for Aggressive Blood Cancer
The FDA has accepted and fast-tracked BeOne Medicines’ new drug sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, a rare and fast-growing blood cancer.
UBS Downgrades Biohaven on Pipeline Setbacks
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.